Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce E Johnson

Showing results (151-160 of 284) with videos related to

Pageof 29
Sort By:
Lung Cancer (Amsterdam, Netherlands)|September 24, 2022
Safety of image guided research biopsies in patients with thoracic malignanciesSteffan K Soosman, Matthew P Schenker, Emanuele Mazzola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistryMari Mino-Kenudson, Lucian R Chirieac, Kenny Law, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 13, 2018
A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural MesotheliomaBryan M Burt, William G Richards, Hyun-Sung Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2007
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancerJohn V Heymach, Bruce E Johnson, Diane Prager, et al.
Lung Cancer (Amsterdam, Netherlands)|November 30, 2024
Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB studyIbiayi Dagogo-Jack, Alissa J Cooper, Bruce E Johnson, et al.
Oncotarget|March 19, 2015
A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancerDavid M Jackman, Leigh A Cioffredi, Lorraine Jacobs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2005
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerRoy S Herbst, Diane Prager, Robert Hermann, et al.
Chest|June 28, 2021
Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced Non-small Cell Lung CancerAdam H Fox, James R Jett, Upal Basu Roy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2009
Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancerPanos Fidias, Nathan A Pennell, Anthony L Boral, et al.
JCO Precision Oncology|February 9, 2022
Outcomes by <i>EGFR</i>, <i>KRAS</i>, and <i>ALK</i> Genotype After Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung CancerRaymond H Mak, Gretchen Hermann, Hugo J Aerts, et al.
Pageof 29

Showing results (151-160 of 284) with videos related to

Sort By:
Pageof 29
Lung Cancer (Amsterdam, Netherlands)|September 24, 2022
Safety of image guided research biopsies in patients with thoracic malignanciesSteffan K Soosman, Matthew P Schenker, Emanuele Mazzola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistryMari Mino-Kenudson, Lucian R Chirieac, Kenny Law, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 13, 2018
A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural MesotheliomaBryan M Burt, William G Richards, Hyun-Sung Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2007
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancerJohn V Heymach, Bruce E Johnson, Diane Prager, et al.
Lung Cancer (Amsterdam, Netherlands)|November 30, 2024
Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB studyIbiayi Dagogo-Jack, Alissa J Cooper, Bruce E Johnson, et al.
Oncotarget|March 19, 2015
A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancerDavid M Jackman, Leigh A Cioffredi, Lorraine Jacobs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2005
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerRoy S Herbst, Diane Prager, Robert Hermann, et al.
Chest|June 28, 2021
Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced Non-small Cell Lung CancerAdam H Fox, James R Jett, Upal Basu Roy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2009
Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancerPanos Fidias, Nathan A Pennell, Anthony L Boral, et al.
JCO Precision Oncology|February 9, 2022
Outcomes by <i>EGFR</i>, <i>KRAS</i>, and <i>ALK</i> Genotype After Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung CancerRaymond H Mak, Gretchen Hermann, Hugo J Aerts, et al.
Pageof 29